In this proof-of-concept study, we took advantage of an existing panel of dual GSK-3β/HDAC inhibitor candidates generated for the treatment of AD and demonstrated that these compounds could reduce the growth of Mtb inside human macrophages. This evidence concerns the gene HDAC9 and Alzheimer disease.